Vladimír Maisnar
A5081608320- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Phytochemical compounds biological activities
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Glycosylation and Glycoproteins Research
- Cancer therapeutics and mechanisms
- HIV/AIDS drug development and treatment
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Research on Leishmaniasis Studies
- Immunodeficiency and Autoimmune Disorders
- Cancer Mechanisms and Therapy
- Hematological disorders and diagnostics
- Beetle Biology and Toxicology Studies
- Glioma Diagnosis and Treatment
- Education, Psychology, and Social Research
- Testicular diseases and treatments
- Clinical Laboratory Practices and Quality Control
- Quinazolinone synthesis and applications
University Hospital Hradec Králové
2016-2025
Charles University
2016-2025
University of Hradec Králové
2018-2023
Hospital Universitario Son Espases
2023
National and Kapodistrian University of Athens
2023
St. Charles Hospital
2021
Division of Chemistry
2015
University Teaching Hospital
2014
Masaryk University
2007
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and has shown efficacy in phase 1 2 study
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed refractory multiple myeloma (RRMM). Relapsed patients were randomized (1:1) to receive (10-min intravenous infusion; 20 mg/m2 on days 1 2 of cycle 1; 27 thereafter) or a control regimen (84 mg dexamethasone equivalent corticosteroid) with (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred...
Summary Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV) infusion multiple myeloma (MM). We describe the Phase II PLEIADES study of subcutaneous formulation daratumumab (DARA SC) in combination with standard‐of‐care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D‐VRd) transplant‐eligible newly diagnosed MM (NDMM); bortezomib/melphalan/prednisone (D‐VMP) transplant‐ineligible NDMM; and lenalidomide/dexamethasone (D‐Rd) relapsed/refractory MM....
Abstract TOURMALINE‐MM1 is a phase III, randomized, double‐blind, placebo‐controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo‐Rd in patients with relapsed/refractory multiple myeloma following 1–3 prior lines therapy. The met its primary endpoint, demonstrating significantly longer progression‐free survival (PFS) the IRd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, P = .01), limited additional toxicity. Patient‐reported health‐related quality life...
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present a monoclonal gammopathy undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized its clinical is properly validated.An algorithm having MGUS-like was developed on the basis percentages total bone marrow (BM) plasma cells (PC) clonal PC within BM compartment, determined at diagnosis using flow cytometry in 548 MGUS 2,011...
Abstract IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out multicenter retrospective study in patients with diagnosis of defined by >10% marrow involvement monoclonal plasma cells, presence an paraproteinemia any size, anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified FISH. A total 134 from 20 centers were included this analysis. The median age at...
In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) response rates versus lenalidomide (Rd) in patients with relapsed multiple myeloma. Per protocol, received KRd for a maximum of 18 cycles followed by Rd to progression, so the benefit/risk profile progression was not established. This post hoc analysis evaluated efficacy safety at months from randomization. Cumulative complete (CR) or better over time PFS hazard ratio (HR)...
Abstract Background We have performed a head to comparison of all-oral triplet combination ixazomib, lenalidomide and dexamethasone (IRD) versus (RD) in patients with relapsed refractory multiple myeloma (RRMM) the routine clinical practice. Methods A total 344 treated IRD ( N = 127) or RD 217) were selected for analysis from Czech Registry Monoclonal Gammopathies (RMG). Descriptive statistics used assess patient’s characteristics associated respective therapy. The primary endpoint was...
Objective Subcutaneous (SC) application of bortezomib has been recently introduced as a new route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes bortezomib-based therapy patients treated using either intravenous (IV) or subcutaneous administration. Patients and methods During January 2012 through December 2013, we retrospective 446 with MM regimens (either once weekly – 63% twice 27%) both, first line setting, relapse, separate undergoing autologous stem...
Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only few cases of skin involvement have been reported, primarily single case reports. We analyzed and present the outcomes, immunohistochemistry cytogenetic features, relevant laboratory data on 53 biopsy-proven MM cases. The median time from diagnosis to was 2 years. There appears be an overrepresentation immunoglobulin class A (IgA) light chain disease MM. found no correlation between CD56 negative infiltration....
The prognostic impact of chromosomal abnormalities was evaluated by fluorescence in situ hybridization with cytoplasmic immunoglobulin light chain staining (cIg-FISH) and classical metaphase cytogenetics a cohort 207 patients newly diagnosed multiple myeloma who were treated high-dose therapy followed autologous stem cell transplantation the CMG2002 clinical trial. incidence detected FISH as follows: 52.7% for del(13)(q14), 6.5% del(17)(p13), 18.6% t(11;14)(q13;q32), 22.8% t(4;14)(p16;q32)...
Patients with relapsed/refractory multiple myeloma (RRMM) experience several relapses, and become refractory to successive therapies. In the ICARIA-MM trial (NCT02990338), isatuximab plus pomalidomide-dexamethasone prolonged median progression-free survival (PFS) in patients RRMM. This subgroup analysis of assessed treatment benefit by prior lines therapy status. A total 307 were randomized isatuximab-pomalidomide-dexamethasone (n = 154) or 153). Isatuximab (10 mg/kg intravenously) was given...
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma routine clinical practice. Patients & methods: Patient-level data from global, observational INSIGHT MM Czech Registry Monoclonal Gammopathies were integrated analyzed. Results: At cut-off, 263 patients 13 countries included. Median time diagnosis to start IRd was 35.8 months; median duration follow-up 14.8 months. Overall response rate 73%, progression-free...
Multiple myeloma (MM) is a cancer of plasma cells with an incidence 4.8 cases per 100,000 population in the Czech Republic 2014; burden MM moderate when compared to other European countries. This work brings latest information on epidemiology population.The National Cancer Registry basic source data for population-based evaluation epidemiology. database also makes it possible assess patient survival and predict probable short-term as well long-term trends treatment entire...